Correlation Between EGFR Mutation Using cfDNAs and Circulating Tumor Cells in Patients With NSCLC
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02422628|
Recruitment Status : Unknown
Verified December 2016 by National Taiwan University Hospital.
Recruitment status was: Enrolling by invitation
First Posted : April 21, 2015
Last Update Posted : December 14, 2016
|Condition or disease|
|Study Type :||Observational|
|Estimated Enrollment :||400 participants|
|Official Title:||Correlation Between Epithelial Growth Factor Receptor(EGFR) Mutation Using cfDNA and CTCs in Patients With Non-Small Cell Lung Cancer|
|Study Start Date :||April 2015|
|Estimated Primary Completion Date :||December 2018|
|Estimated Study Completion Date :||December 2018|
EGFR mutation postive
Blood samples every 3 months till disease progression or intolerable due to side effect.
EGFR mutation wild type
Blood samples before treatment once.
Blood samples once.
- Progressive disease measured by RECIST criteria after receiving 1st line EGFR-TKI [ Time Frame: 3 years ]
Biospecimen Retention: Samples With DNA
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02422628
|National Taiwan University Hospital|
|Taipei city, Taiwan, 100|
|Principal Investigator:||Chao-Chi Ho||National Taiwan University Hospital No. 7, Chung-Shan South Road, Taipei, Taiwan|